Plain-English translation of NCT06638502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called HRX215 to see if it can help your liver recover after surgery to remove cancer spots. The study will first test the medication in a small group of patients who have had minor liver surgery, then move to a larger group who have had major liver surgery. Researchers want to make sure the medication is safe and that it helps the liver grow back properly after the operation.
After liver surgery, especially removing a large portion of the liver, patients face a serious risk of liver failure during recovery. This medication is being tested to see whether it can support the liver's natural healing process and reduce this dangerous complication.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication or a placebo twice daily for 28 days, starting before or shortly after your liver surgery. You'll have daily check-ins at the hospital for the first week, then visits every two weeks, with follow-up visits at 3 and 6 months after starting treatment. The study team will do blood tests and imaging scans to monitor how your liver is healing and to make sure the medication is safe.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
France